MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in TransMedics Group, Inc. (NASDAQ:TMDX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,657 shares of the company’s stock after acquiring an additional 1,096 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of TransMedics Group worth $1,163,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Janney Montgomery Scott LLC purchased a new stake in TransMedics Group in the fourth quarter worth about $239,000. Cornerstone Wealth Management LLC bought a new position in TransMedics Group in the fourth quarter worth approximately $231,000. Sachetta LLC bought a new position in TransMedics Group in the fourth quarter worth approximately $40,000. Perigon Wealth Management LLC lifted its holdings in TransMedics Group by 212.4% during the fourth quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company’s stock worth $828,000 after buying an additional 9,707 shares during the period. Finally, Clear Creek Financial Management LLC purchased a new position in shares of TransMedics Group in the 4th quarter valued at $352,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on TMDX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Finally, Oppenheimer increased their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $126.70.

TransMedics Group Stock Up 0.7%

Shares of NASDAQ:TMDX opened at $124.25 on Monday. The firm has a market capitalization of $4.20 billion, a PE ratio of 132.18 and a beta of 1.91. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm’s 50-day moving average is $89.57 and its two-hundred day moving average is $77.17.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. Analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the business’s stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David Weill sold 732 shares of the business’s stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now directly owns 12,134 shares of the company’s stock, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.